Gourlay ML. Salmon calcitonin use and associated cancer risk. Ann Pharmacother. 2013 Dec;47(12):1675-84. \[[PubMed: 24259626](https://pubmed.ncbi.nlm.nih.gov/24259626)\] 30. Ishii J, Katayama S, Itabashi A, Takahama M, Kawazu S. Salmon calcitonin induces pituitary tumor in rats. Endocrinol Jpn. 1991 Dec;38(6):705-9. \[[PubMed: 1823038](https://pubmed.ncbi.nlm.nih.gov/1823038)\] 31. Sondergaard BC, Catala-Lehnen P, Huebner AK, Bay-Jensen AC, Schinke T, Henriksen K, Schilling S, Haberland M, Nielsen RH, Amling M, Karsdal MA. Mice over-expressing salmon calcitonin have strongly attenuated osteoarthritic histopathological changes after destabilization of the medial meniscus. Osteoarthritis Cartilage. 2012 Feb;20(2):136-43. \[[PubMed: 22122987](https://pubmed.ncbi.nlm.nih.gov/22122987)\] 32. Wells G, Chernoff J, Gilligan JP, Krause DS. Does salmon calcitonin cause cancer? A review and meta-analysis. Osteoporos Int. 2016 Jan;27(1):13-9. \[[PMC free article: PMC4715844](/pmc/articles/PMC4715844/)\] \[[PubMed: 26438308](https://pubmed.ncbi.nlm.nih.gov/26438308)\] 33. Tanaka S, Yoshida A, Kono S, Ito M. Effectiveness of monotherapy and combined therapy with calcitonin and minodronic acid hydrate, a bisphosphonate, for early treatment in patients with new vertebral fractures: An open-label, randomized, parallel-group study. J Orthop Sci. 2017 May;22(3):536-541. \[[PubMed: 28108224](https://pubmed.ncbi.nlm.nih.gov/28108224)\] **Disclosure:** Matthew McLaughlin declares no relevant financial relationships with ineligible companies. **Disclosure:** Ayoola Awosika declares no relevant financial relationships with ineligible companies. **Disclosure:** Ishwarlal Jialal declares no relevant financial relationships with ineligible companies.